行情

RGLS

RGLS

Regulus
NASDAQ

实时行情|Nasdaq Last Sale

0.8000
-0.0400
-4.76%
休市 16:00 09/20 EDT
开盘
0.8397
昨收
0.8400
最高
0.8598
最低
0.8000
成交量
19.45万
成交额
--
52周最高
3.140
52周最低
0.5026
市值
1,665.97万
市盈率(TTM)
-0.2891
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RGLS 新闻

  • 日美贸易协定冲击波:部分日本农民或“失业”
  • 中国经营报.5小时前
  • 亚马逊曾拟1500万美元收购奈飞 现在奈飞市值超千亿
  • 新浪美股.8小时前
  • 沙特称伊朗应为石油设施遇袭负责 伊方驳斥:毫无根据
  • 央视.9小时前
  • 软银计划披露对拉美巨额投资 "将带40家公司去巴西"
  • 新浪美股.9小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

RGLS 简况

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
展开

Webull提供Regulus Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。